Biotechnology stocks are showing signs of a renewed recovery, supported by a pickup in pharmaceutical mergers and acquisitions and investor interest in drug development pipelines. Key Takeaways: Big pharma acquisitions are hitting record highs to combat impending patent cliffs. Institutional capital and leveraged funds are surging while retail investors remain deeply cautious. Performance varies heavily [...]
The post Biotech’s Rebound Reality: Surging M&A Deals Meet Deep Retail Skepticism appeared first on ETF Trends.